Aug. 20 at 2:05 PM
$CHRS During the Conference Call on August 8, 2025, CEO Denny Lanfear emphasized the company’s strategy to advance its mission through partnerships, particularly for its pipeline assets, including LOQTORZI . While specific new partners were not named beyond the existing collaboration with STORM Therapeutics for a Phase 1b/2 study combining LOQTORZI with STC-15, Lanfear highlighted a focus on securing additional partnership opportunities in the next 6-9-12 months to evaluate LOQTORZI in combination with novel cancer agents. The Co. aims to expand LOQTORZI’s indications cost-effectively through clinical trial collaboration and supply agreements, where partners sponsor trials and Coherus provides LOQTORZI. Additionally, Coherus is exploring ex-US licensing opportunities to enhance its oncology portfolio, with a goal of creating significant value for its U.S.-focused business. Partnerships are expected to leverage proven track record in deal-making to drive clinical and strategic progress
